In the second half of 2024, several key patent cases will capture the attention of legal professionals, with significant implications for patent law and pharmaceutical regulations. Among the pivotal cases to watch is a U.S. Supreme Court case delving into the judicially created double patenting doctrine’s reach. This case will examine the extent to which this doctrine, which prevents a patentee from extending the life of a patent by obtaining additional patents, should be applied.
Another critical case involves a dispute concerning which patents branded drugmakers can list in the federal “Orange Book” database. The outcome of this dispute is poised to impact how pharmaceutical companies protect their products and maintain market exclusivity. For an in-depth analysis, visit the full article on Law360.